Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Effects of rituximab on lymphocytes in multiple sclerosis and neuromyelitis optica.
MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial
IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H).
Apitope Announces Positive Results from Clinical Trial of ATX-MS-1467 in Relapsing Multiple Sclerosis
Stress signaling etches heritable marks on chromatin.
Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer.
Activation of axonal Kv7 channels in human peripheral nerve by flupirtine but not placebo - therapeutic potential for peripheral neuropathies: results of a randomised controlled trial.
Differential effects of fingolimod on B-cell populations in multiple sclerosis.
Gut microbiota composition and relapse risk in pediatric MS: A pilot study.
Overcoming barriers in progressive multiple sclerosis research.
Phase II Cladribine Add-on to Interferon-beta (IFN-b) Therapy in MS Subjecs With Active Disease (ONWARD)
Dalfampridine sustained-release for symptomatic improvement of walking speed in patients with multiple sclerosis.
Autologous attenuated T-cell vaccine (Tovaxin) dose escalation in multiple sclerosis relapsing-remitting and secondary progressive patients nonresponsive to approved immunomodulatory therapies.
Saccadic intrusions: review and update.
Normal-appearing white matter in multiple sclerosis is in a subtle balance between inflammation and neuroprotection.
The Stigma Scale for Chronic Illnesses 8-Item Version (SSCI-8): Development, Validation and Use Across Neurological Conditions.
Microglia activation is associated with IFN-α induced depressive-like behavior.
Combined central and peripheral demyelination: Clinical features, diagnostic findings, and treatment.
Glatiramer acetate does not protect from acute ischemic stroke in mice.
A complex role of herpes viruses in the disease process of multiple sclerosis.
Does interferon Beta-1a impact pure-tone hearing sensitivity among individuals with multiple sclerosis?
In vivo gene expression revealed by cDNA arrays: the pattern in relapsing-remitting multiple sclerosis patients compared with normal subjects.
Monoclonal antibodies conjugated with superparamagnetic iron oxide particles allow magnetic resonance imaging detection of lymphocytes in the mouse brain.
Rescue Therapy Using Rituximab for Multiple Sclerosis.
Modeling probability of additional cases of natalizumab-associated JCV sero-negative progressive multifocal leukoencephalopathy.
Pages
« first
‹ previous
…
128
129
130
131
132
133
134
135
136
…
next ›
last »